April 24 (Reuters) - Germany's Merck KGaA MRCG.DE is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics SWTX.O, the Wall Street Journal reported on Thursday, citing people familiar with the matter.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.